Chamber and committees

Information about aggregate grant funding for individual non-national museums is not held centrally. However, the Scottish Museums Council has provided the following details of its disbursements on behalf of the Scottish Executive:

Type of Museum	2000-01	2001-02	2002-03	2003-04	2004-05
Independent (£)	53,284	456,354	582,965	583,719	387,344
Local authority (£)	81,775	88,309	426,170	535,261	1,030,670
Regimental (£)	433	8,423	1,139	534	13,295
University (£)	9,535	20,376	152,831	164,054	31,245
Total (£)	145,027	573,462	1,163,105	1,283,568	1,462,554

 

The preferred source for earnings estimates is the Annual Survey of Hours and Earnings (ASHE), which is carried out by the Office for National Statistics.

The following table gives the median gross weekly pay for full-time employee jobs by gender.

Table 1 Median¹ Gross Weekly Pay (£) for Full-Time Employee Jobs², Broken Down by Gender, Scotland 1997 to 2004.

Year	Male	Female	All
19973	378.0	272.4	336.8
1998	357.1	256.9	313.8
1999	370.0	274.6	329.0
2000	380.5	280.9	338.4
2001	398.2	296.7	355.1
2002	414.4	311.0	371.7
2003	419.2	326.0	381.3
2004	433.2	345.5	394.5

Source: 1997, New Earnings Survey (NES), 1998 to 2004, Annual Survey of Hours and Earnings.

Notes:

1. The median is the value below which 50 per cent of employee jobs fall. It is preferred over an arithmetic average for earnings data as it is influenced less by large or extreme values.

2. Employees on adult rates whose pay for the survey pay-period was not affected by absence.

3. ASHE data is currently only available from 1998 onwards. Prior to 1998 the preferred source of earnings data was the New Earnings Survey (NES). However, caution should be used when comparing data from NES and ASHE as they are not directly comparable.

“Bowel cancer” has been interpreted as referring to cancer of the large bowel which is also known as colorectal cancer.

Table (a) shows the number of people diagnosed with colorectal cancer between 1995 and 2001 by NHS board area. 2001 is the most recent year for which incidence data is complete. Table (b) shows the number of people who died from colorectal cancer between 1998 and 2004 by NHS board area.

While cancer incidence continues to rise, death rates overall are reducing, as projected in Cancer Scenarios (Scottish Executive 2001, updated 2004). Earlier detection and improved treatments are contributing to these encouraging improvements in survival.

More comprehensive data on colorectal cancer can be found on the Scottish Health Statistics website at www.isdscotland.org\cancer_information.

Table (a): Number of People Diagnosed with Colorectal Cancer Between 1995 and 2001 by NHS Board Area of Residence

NHS Board Area	Year of Diagnosis
	1995	1996	1997	1998	1999	2000	2001
Argyll and Clyde	295	302	286	277	270	303	318
Ayrshire and Arran	236	286	267	269	265	261	277
Borders	85	110	95	82	87	90	81
Dumfries and Galloway	110	121	114	110	102	109	98
Fife	230	255	221	221	237	275	278
Forth Valley	153	187	169	157	173	167	179
Grampian	333	354	312	388	362	371	415
Greater Glasgow	623	660	577	557	571	552	590
Highland	136	161	175	139	156	171	162
Lanarkshire	271	304	324	306	310	319	287
Lothian	489	474	509	453	510	518	463
Orkney	14	14	9	17	19	14	11
Shetland	20	13	21	13	15	19	17
Tayside	287	330	304	310	340	366	323
Western Isles	16	27	28	30	27	23	24
Scotland	3,298	3,598	3,411	3,329	3,444	3,558	3,524

Source: Scottish Cancer Registry, date extracted: August 2005.

Table (b): Number of People who Died from Colorectal Cancer Between 1998 and 2004 by NHS Board Area of Residence

NHS Board Area	Year of Death Registration
	1998	1999	2000	2001	2002	2003	2004
Argyll and Clyde	145	107	140	131	121	122	131
Ayrshire and Arran	130	136	112	119	116	110	124
Borders	37	54	38	44	45	50	48
Dumfries and Galloway	58	68	55	56	55	56	56
Fife	109	116	102	131	104	94	103
Forth Valley	75	86	78	82	97	106	76
Grampian	171	179	173	154	157	182	177
Greater Glasgow	274	278	275	286	269	257	274
Highland	72	77	70	75	63	74	62
Lanarkshire	135	147	152	134	164	148	149
Lothian	231	218	214	236	191	220	203
Orkney	11	6	4	7	3	6	3
Shetland	12	5	6	9	9	6	12
Tayside	167	165	162	147	145	139	124
Western Isles	12	20	15	4	16	12	8
Scotland	1,639	1,662	1,596	1,615	1,555	1,582	1,550

Source: General Register Office for Scotland, date extracted: August 2005.

Invitations are sent out to all men and women aged 50 to 69 registered with a GP Practice, along with a faecal occult blood test (FOBt) kit, instruction and information leaflets. A reminder letter is sent after four to six weeks if there has been no response to the initial invitation.If an individual has a positive FOBt results they will be referred to their localhospital for assessment and offered further investigations, if appropriate.

(a): The following table shows numbers of invitations sent out for bowel screening, numbers of people screened and the percentage uptake in rounds 1 and 2 of the bowel screening pilot programme, by NHS board.

Bowel Screening Pilot (Round 1 and 2): Invitations and Uptake, by NHS Board

	Health Board			Total
	Fife	Grampian	Tayside
Number of people invited in Round 1 (April 2000 – September 2002)	83,591	122,784	97,870	304,245
Number of people completing FOBt1 screening in Round 1	44,435	69,012	53,968	167,415
Percentage uptake of FOBt1 screening in Round 1	53.2%	56.2%	55.1%	55.0%
Number of people invited in Round 22 (December 2002 – January 2005)	85,350	125,946	98,487	309,783
Number of people completing FOBt1 screening in Round 2	43,024	68,348	52,687	164,059
Percentage uptake of FOBt1 screening in Round 2	50.4%	54.3%	53.5%	53.0%

Source: Scottish Bowel Screening Programme, ISD. Round 1 data extracted: Feb 2005, Round 2 data extracted: July 2005

Notes:

1: Faecal occult blood test.

2: Data for Round 2 of the bowel cancer screening pilot are currently considered provisional.
3: Data only include people invited to screen as part of the bowel cancer screening pilot and do not include those who may have attended a private screening.

(b): The following table shows numbers of invitations sent out for bowel screening, numbers of people screened and the percentage uptake in rounds 1 and 2 of the bowel screening pilot programme, by age group.

Bowel Screening Pilot (Round 1 and 2): Invitations and Uptake, by Age Group

	Age Group (Years)						Total
	<>2	50-54	55-59	60-64	65-69	>692
Number of people invited in Round 1 (April 2000 – September 2002)	8,243	91,995	74,138	64,844	58,972	6,053	304,245
Number of people completing FOBt1 screening in Round 1	3,788	47,655	40,835	37,515	34,442	3,180	167,415
Percentage uptake of FOBt1 screening in Round 1	46.0%	51.8%	55.1%	57.9%	58.4%	52.5%	55.0%
Number of people invited in Round 23 (December 2002 – January 2005)	5,604	85,337	84,895	66,628	59,383	7,936	309,783
Number of people completing FOBt1 screening in Round 2	2,496	40,126	44,659	37,451	34,854	4,473	164,059
Percentage uptake of FOBt1 screening in Round 2	44.5%	47.0%	52.6%	56.2%	58.7%	56.4%	53.0%

Source: Scottish Bowel ScreeningProgramme, ISD. Round 1 data extracted: Feb 2005, Round 2 data extracted: July 2005

1: Faecal occult blood test.

2: Individuals <50 and="">69years may be invited to participate as the IT system calls individuals in yearsof birth and not by birth date.

3: Data for Round 2 of the bowelcancer screening pilot are currently considered provisional.
4: Data only include people invited to screen as part of the bowel cancer screeningpilot and do not include those who may have attended a private screening.

The Department of Health commissioned a team from Edinburgh, Warwick and Essex Universities to formally evaluate the Cancer Challenge screening pilot which ran in England and Scotland from April 2000 to December 2002. The target UK population was approximately 300,000 over the screening period.

The following key outcomes are collated from the formal evaluation report submitted to the Department of Health in 2003 (this can be viewed online at http://www.cancerscreening.nhs.uk/bowel/finalreport.pdf) and also further statistical analysis of the complete dataset by NHS Information Services Division.

Screening for bowel cancer with faecal occult blood test (FOBt) kits in the general population is feasible and should be rolled out to a national programme.

Overall uptake of screening in Scotland was 50.4% for males, 59.5% for females and 55% overall.

Greater number of early stage cancers detected in the population being screened compared to the population that have not been screened (Dukes A: screened population 22.5%, non-screened population 12.6%).

Uptake rates influenced by deprivation (Both sexes: least deprived 62.1% compared to most deprived 41.2% by Scottish Index of Multiple Deprivation).

UK pilot had a considerable impact on workload in secondary care including increased demand for non-screening colonoscopy services and a substantial impact on pathology services.

The impact on primary care was modest.

Systematic review indicates that FOBt screening costs approximately £2,000 per Quality Adjusted Life Year and appears relatively cost effective – at this level FOBt screening is well within arbitrary “efficiency” thresholds and commensurate with other population based cancer screening programmes.

I refer the member to the answer to question S2W-18315 on 31 August 2005. All answers to written parliamentary questions are available on the Parliament's website, the search facility for which can be found at http://www.scottish.parliament.uk/webapp/wa.search.

I announced recently that a Scottish bowel cancer screening programme for all men and women aged from 50 to 74 will be rolled out from March 2007, with all health boards involved in the programme by 2009. This follows a successful pilot which has been running in Tayside, Grampian and Fife Health Board areas since 2000. As at January 2005 over 330,000 people have been screened for bowel cancer in these three areas.

All individuals in the screening age range will be invited to complete a test kit at home every two years. Returned kits will be screened at a central laboratory, call/recall and helpline facility, based at Dundee’s Kings Cross. Individuals with a non-negative result will then be invited for follow-up investigation. We expect to reduce mortality rates in the target population by 15%, potentially preventing over 150 lives being lost to bowel cancer per year.

We have already made available £2 million of capital funding to finance the extension of the Dundee laboratory and the development of a new IT system in order to prepare for national rollout of the programme.

The UK Colorectal Cancer Screening pilot commenced in April 2000 and included both Scottish and English programmes. Men and women aged from 50 to 69 were invited to complete a home test kit with returned kits being screened at laboratories in England and Scotland. An evaluation report on the UK pilot published in July 2003, (this can be viewed online at http://www.cancerscreening.nhs.uk/bowel/finalreport.pdf) confirmed the potential benefits of bowel cancer screening.

Key Performance Indicators (KPIs) were collated by the Scottish and English teams throughout the pilot to monitor its effectiveness. A selection of the KPIs, such as overall uptake of screening, positivity rate and cancer/adenoma detection rates, will be used to assess results on a UK basis during national rollout of bowel cancer screening in Scotland which commences in March 2007.

The Chief Scientist Office (CSO) within the Scottish Executive Health Department funded a study, which completed in February 2001. It assessed theories on how VRE is spread and methods of control in high dependency units. The study found that the type of vancomycin-resistance that is found may be influenced by the way in which antibiotics are prescribed. A greater understanding of the pattern of resistance will help to identify the therapeutic options likely to be effective. Guidance on prudent antibiotic prescribing in hospitals will be published in the very near future.

The CSO is not currently funding any research into VRE, but would be pleased to consider research proposals for innovative VRE studies of a sufficiently high standard. These would be subject to the usual peer and committee review.

Details of further UK research studies that have been undertaken on VRE can be found on the National Research Register.

The information requested isgiven in the following table.

Percentage of deaths occurringat the deceased’s usual address in each health board area in Scotland in 2004

Argyll and Clyde	21%
Ayrshire and Arran	19%
Borders	19%
Dumfries and Galloway	23%
Fife	19%
Forth Valley	18%
Grampian	19%
Greater Glasgow	20%
Highland	22%
Lanarkshire	21%
Lothian	18%
Orkney	29%
Shetland	25%
Tayside	20%
Western Isles	24%
All Scotland	20%

 

As the table shows, there arerelatively small variations from the Scottish mean of 20%. The most significantvariations occur in the Island NHS board areas. This is likely to reflect a rangeof factors including choices made by individuals and families in consultation withthe relevant General Practitioner, other social factors, and geography.